Showing results (11-20 of 121) with videos related to
Sort By:
Pageof 13
Medizinische Klinik (Munich, Germany : 1983)|June 22, 2005
[Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG]Michael SchlanderCurrent Medical Research and Opinion|February 19, 2008
Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE)Michael SchlanderExpert Review of Pharmacoeconomics & Outcomes Research|December 18, 2018
Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?Ramon Schaefer, Michael SchlanderHealth and Quality of Life Outcomes|November 11, 2023
Measurement invariance and adapted preferences: evidence for the ICECAP-A and WeRFree instrumentsJasper Ubels, Michael SchlanderCancer Medicine|May 11, 2021
Income loss after a cancer diagnosis in Germany: An analysis based on the socio-economic panel surveyDiego Hernandez, Michael SchlanderJournal of Market Access & Health Policy|November 19, 2016
Determining the value of medical technologies to treat ultra-rare disorders: a consensus statementMichael Schlander, Silvio Garattini, Peter Kolominsky-Rabas, et al.MMW Fortschritte Der Medizin|December 11, 2007
[Children with attention deficit hyperactivity disorder in school]Götz-Erik Von Trott, Michael SchlanderPharmacoeconomics - Open|April 13, 2026
Exploring the Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI3, 15D, AQoL-4D, and AQoL-8D Multi-Attribute Utility Instruments to SF-36 DimensionsJosephine N A Tetteh, Michael SchlanderExpert Review of Pharmacoeconomics & Outcomes Research|December 21, 2013
Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelorAfschin Gandjour, Amiram Gafni, Michael SchlanderJournal of Comparative Effectiveness Research|October 3, 2014
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disordersMichael Schlander, Silvio Garattini, Søren Holm, et al.Pageof 13